Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Plovdiv, Bulgaria, 4002
- Clinic of Rheumatology at MHAT 'Sveti Georgi'
-
Sofia, Bulgaria, 1612
- Clinic of Rheumatology at MHAT 'Sveti Ivan Rilski'
-
Sofia, Bulgaria
- Clinic of internal diseases at NMTH 'Tzar Boris Treti'
-
Stara Zagora, Bulgaria, 6000
- Second Clinic of Internal Diseases at MHAT 'Stara Zagora'
-
Varna, Bulgaria, 9010
- Clinic of Rheumatology at MHAT 'Sveta Marina' - Varna
-
-
-
-
-
Hradec Kralove, Czechia, 50005
- University Hospital Hradec Kralove
-
Prague, Czechia, 12850
- Institute of Rheumatology
-
Zlin, Czechia, 76001
- Rheumotology Out-patient Clinic
-
-
-
-
-
Afula, Israel
- Haemek Medical Center
-
Ashkelon, Israel, 78278
- Barzilai Medical Center
-
Haifa, Israel, 31096
- Rambam Medical Center
-
Jerusalem, Israel
- Hadassah Har-Hazofim Medical Center
-
Kfar-Saba, Israel, 44281
- Meir Medical Center
-
-
-
-
-
Elblag, Poland, 82300
- Wojewodzki Szpital Zespolony w Elblagu
-
Lublin, Poland, 20607
- Niepubliczny Zaklad Opieki Zdrowotnej
-
Sopot, Poland, 81967
- Wojewodzki Zespol Reumatologiczny w Sopocie
-
Szczecin, Poland, 71252
- Samodzielny Publiczny Szpital Kliniczny Nr 1 P.A.M. w Szczecinie
-
Torun, Poland, 87100
- Niepubliczny Zaklad Opieki Zdrowotnej "NASZ LEKARZ"
-
-
-
-
-
Belgrade, Serbia, 11000
- Institute of Rheumatology - Belgrade
-
Niska Banja, Serbia, 18205
- Institute for Prevention, Treatment, and Rehabilitation of Rheumatoid and Cardiovascular Diseases Niska Banja
-
-
-
-
-
Donetsk, Ukraine, 83114
- Central Municipal Clinical Hospital nº1
-
Kiev, Ukraine, 01023
- Kyiv Central Municipal Hospital
-
Kiev, Ukraine, 01103
- City Clinical Hospital N12
-
Kiev, Ukraine, 03680
- National Scientific Centre of AMS of Ukraine
-
Kiev, Ukraine, 04053
- O.O. Bogomolets National Medical University
-
Vinnycia, Ukraine, 21018
- Vinnitsya Regional Clinical Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females ages 18-75 years
- Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al. Arthritis Rheum 1988;31:315-324; refer to Appendix 1. diagnostic criteria for Rheumatoid Arthritis)
- Not bed- or wheelchair-bound
- Active RA, as indicated by the presence of (a) >=6 swollen joints (28 joint count); AND (b) >=6 tender joints (28 joint count); AND either: (c) Westergren ESR of >=28 mm/hour; OR (d) CRP level above the upper limit of normal for the central reference laboratory
- Treatment with weekly oral or parenteral methotrexate for >=6 months prior to baseline
- Methotrexate route of administration has been unchanged for >=2 months prior to baseline
- Dose of methotrexate has been stable at 15-25 mg/week for >=2 months, and is expected to remain stable throughout the study; the stable dose of methotrexate may alternatively be 10-12.5 mg/week if documented toxicity has precluded a higher dose
- If taking hydroxychloroquine or chloroquine, administration duration has been for >=3 months and dose has been stable for >=2 months prior to baseline
- If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at least 1 month prior to baseline, and will remain unchanged during protocol participation
- If taking an oral corticosteroid, dose is <10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the stabilization period, and will remain stable through the stabilization and entire treatment and follow-up period
- Negative screening serum pregnancy test for female patients of childbearing potential
- Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method)
Exclusion Criteria:
- Receipt of any of the following for at least a 1 month stabilization period prior to dosing: sulfasalazine, oral or injectable gold, azathioprine, minocycline, penicillamine, anakinra
- Receipt of etanercept for at least a 6 week period prior to dosing
- Receipt of cyclosporine, infliximab or adalimumab for at least a 2 month period prior to dosing
- Receipt of leflunomide for at least a 2 month period prior to screening, unless patient has undergone cholestyramine washout at least 1 month prior to dosing
- Receipt of cyclophosphamide for at least a 6 month period prior to dosing
- Receipt of rituximab at any previous time
- Participation in a previous trial CF101 trial
- Use of oral corticosteroids >10 mg of prednisone, or equivalent, per day
- Change in NSAID dose level for 1 month prior to dosing
- Change in oral corticosteroid dose level during the 1 month prior to, or during, the stabilization period vChange in hydroxychloroquine or chloroquine dose level during the 2 months prior to, or during, the stabilization period
- Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to, or during, the stabilization period
- Significant cardiac arrhythmia or conduction block, congestive heart failure, or any other evidence of clinically significant heart disease; other clinically significant findings on screening electrocardiogram (ECG)
- Hemoglobin level <9.0 gm/dL at the screening visit
- Platelet count <125,000/mm3 at the screening visit
- White blood cell count <3000/mm3 at the screening visit
- Serum creatinine level outside the central laboratory's normal limits at the screening visit
- Liver aminotransferase (ALT and/or AST) levels greater than 1.25 times the central laboratory's upper limit of normal at the screening visit
- Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CF101 0.1 mg
CF101 0.1 mg was given orally q12h
|
orally q12h
Other Names:
|
|
Experimental: CF101 1 mg
CF101 1 mg was given orally q12h
|
orally q12h
Other Names:
|
|
Placebo Comparator: Placebo
Matched placebo was given orally q12h
|
orally q12h
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ACR20 at Week 12
Time Frame: 12 weeks
|
Number of patients that achieved 20% response at week 12 in American College of Rheumatology Criteria
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters
Time Frame: 12 weeks
|
ACR20/50/70 responses over time (intent-to-treat [ITT], last observation carried forward [LOCF]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CF101-203RA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.